PMID- 33384227
OWN - NLM
STAT- MEDLINE
DCOM- 20220119
LR  - 20220119
IS  - 1938-0666 (Electronic)
IS  - 1526-8209 (Linking)
VI  - 21
IP  - 4
DP  - 2021 Aug
TI  - Targeted Therapies for Breast Cancer Brain Metastases.
PG  - 263-270
LID - S1526-8209(20)30323-2 [pii]
LID - 10.1016/j.clbc.2020.11.014 [doi]
AB  - The management of breast cancer, the most common cancer in the female population, 
      has changed dramatically over years with the introduction of newer therapies. An 
      increased incidence of brain metastases in recent years has created a challenge 
      for oncologists because this population continues to have a poorer prognosis 
      compared to metastatic breast cancer without central nervous system involvement. 
      Historically, the exclusion of breast cancer patients with brain metastases from 
      clinical trials has made treatment options even more limited. Nonetheless, more 
      recently, this unmet need has been recognized by basic and clinical researchers 
      and has led to the development of targeted therapies with better blood-brain 
      barrier penetration and intracranial efficacy. Here we review targeted therapies 
      directed at human epidermal growth factor receptor type 2 (HER2), vascular 
      endothelial growth factor (VEGF), mammalian target of rapamycin (mTOR), epidermal 
      growth factor receptor (EGFR), cyclin-dependent kinase 4 and 6 (CDK4/6) and 
      poly(ADP-ribose) polymerase (PARP) for breast cancer patients with brain 
      metastases. These therapies aim to be more efficacious and less toxic to 
      represent a paradigm shift in the management of breast cancer brain metastases.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Cali Daylan, Ayse Ece
AU  - Cali Daylan AE
AD  - Department of Medicine, St Elizabeth's Medical Center, Boston, MA; Department of 
      Medicine, Tufts University School of Medicine, Boston, MA. Electronic address: 
      ayseececalidaylan@gmail.com.
FAU - Leone, Jose Pablo
AU  - Leone JP
AD  - Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201201
PL  - United States
TA  - Clin Breast Cancer
JT  - Clinical breast cancer
JID - 100898731
SB  - IM
MH  - Brain Neoplasms/*secondary/*therapy
MH  - Breast Neoplasms/*pathology/*therapy
MH  - Female
MH  - Humans
MH  - *Molecular Targeted Therapy
OTO - NOTNLM
OT  - Blood brain barrier
OT  - Central nervous system
OT  - Metastatic breast cancer
EDAT- 2021/01/02 06:00
MHDA- 2022/01/20 06:00
CRDT- 2021/01/01 05:16
PHST- 2020/07/02 00:00 [received]
PHST- 2020/10/17 00:00 [revised]
PHST- 2020/11/24 00:00 [accepted]
PHST- 2021/01/02 06:00 [pubmed]
PHST- 2022/01/20 06:00 [medline]
PHST- 2021/01/01 05:16 [entrez]
AID - S1526-8209(20)30323-2 [pii]
AID - 10.1016/j.clbc.2020.11.014 [doi]
PST - ppublish
SO  - Clin Breast Cancer. 2021 Aug;21(4):263-270. doi: 10.1016/j.clbc.2020.11.014. Epub 
      2020 Dec 1.